Novo CEO: We want to focus on mature companies
It was a change in the strategy that led Novo A/S to sell the British company Archimedes Pharma to Prostrakan, a part of Japan-based group Kyowa Hakko Kirin, explains CEO Eivind Kolding.
by Viktor Brandt Kærgaard
Novo A/S used to focus on companies in the early commercialization phases, but a change of that strategy to a focus on bigger and more mature companies led to the divestiture of British-based Archimedes Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo-backed company strikes Big Pharma deal
For abonnenter
Novo kicks investments into next gear in 2014
For abonnenter
Novo heads capital injection in blood potassium company
For abonnenter
